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Abstract
Chronic kidney disease is now recognized to be a worldwide problem associated with significant 
morbidity and mortality and there is a steep increase in the number of patients reaching end-stage 
renal disease. In many parts of the world, the disease affects younger people without diabetes or 
hypertension. The costs to family and society can be enormous. Early recognition of CKD may 
help prevent disease progression and the subsequent decline in health and longevity. Surveillance 
programs for early CKD detection are beginning to be implemented in a few countries. In this 
article, we will focus on the challenges and successes of these programs with the hope that their 
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eventual and widespread use will reduce the complications, deaths, disabilities, and economic 
burdens associated with CKD worldwide.
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Recent findings from the Global Burden Disease 2010 study, to which the International 
Society of Nephrology has contributed, have highlighted chronic kidney disease (CKD) as 
an important cause for global mortality.1 The number of deaths from CKD has risen by 
82.3% in the last two decades, the third largest increase among the top 25 causes of death, 
behind HIV/AIDS (396%) and diabetes.1 That kidney disease constitutes a public health 
priority is also underlined by the fact that, worldwide, the number of end-stage renal disease 
patients receiving renal replacement therapy (RRT) is estimated at >1.4 million, with an 
annual growth rate of 8%.2 With a population that is aging, steep increases in the incidence 
of type 2 diabetes mellitus and hypertension are driving this growth, putting an enormous 
burden on health-care resources.3 However, end-stage renal disease represents the tip of the 
iceberg; CKD occurs in ~10% of the population but it must not be assumed that kidney 
disease is entirely contained within the cardiovascular risk envelope. In the developing 
world, up to 40% of those identified with CKD in screening programs do not have diabetes 
or any cardiovascular disease.3,4 Such patients with kidney disease are often young, and the 
health and social costs of the progression of their kidney disease are high and prolonged. 
Thus, early recognition of CKD and concomitant comorbid conditions can potentially slow 
the progression to renal failure, increase longevity, improve quality of life, and reduce 
health-care costs.
Surveillance programs are just beginning to be implemented in a few countries. International 
Society of Nephrology encourages all members of the World Health Organization to 
recognize CKD as a major noncommunicable disease requiring the development of a 
specific health policy for its early detection and treatment.5 This would also entail the 
development of health information systems to capture data in order to better measure the 
incidence and prevalence of renal failure, track patient outcomes, and determine the true 
burden of disease. The following sections highlight some of these efforts with the hope of 
providing a platform that will discuss the challenges and successes of such efforts.
CKD SURVEILLANCE IN THE UNITED STATES OF AMERICA
The US Centers for Disease Control and Prevention’s National CKD Surveillance System
Background—In recent years, CKD has deservedly received attention as a public health 
problem. In 2006, based on a congressional mandate,6 the CDC launched its own CKD 
initiative2 that included the establishment of the first comprehensive CKD Surveillance 
System for the United States. Two teams from the University of California, San Francisco 
and the University of Michigan were funded to work collaboratively with the CDC in 
developing this system.
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Approach and methodology—The principles and methodology for implementation of 
CKD surveillance in the United States have been published previously.7 In summary, the 
‘passive’ surveillance approach is utilized, leveraging existing data from a variety of 
disparate data sources, broadly consisting of data from health-care systems (e.g., the 
Department of Veterans Affairs—VA, or other large administrative health data, e.g., 
Medicare), as well as data obtained from non-health-care sources (e.g., nationally 
representative surveys, such as the National Health and Nutrition Examination Survey—
NHANES).
A unique aspect of this surveillance system is its comprehensiveness and the systematic 
approach adopted for the capture of major domains (topics) related to CKD and specific 
concepts within those topics (measures). Our teams analyze data from multiple data sources 
before uploading them in a standardized manner to the project website.8
RESULTS
With information from 20 different sources, the CKD Surveillance System has the most 
information about CKD available in the United States. The system provides information on 
the following key topics: burden of CKD (prevalence and incidence), burden of risk factors 
for CKD (prevalence of these conditions in the general population), awareness of CKD 
(both in the general population and among providers), health-care quality and processes of 
care for those with CKD, health consequences associated with CKD (including resource 
utilization), and health system capacity to deal with CKD. The surveillance system also 
provides information on special populations (e.g., CKD in children, CKD among organ 
transplant recipients, and so on), and tracks progress on CKD indicators related to the 
objectives of Healthy People 2020.9
Under the six topics listed above, the system provides 136 measures, e.g., family history of 
CKD, with more detailed information. Specific indicators were developed for these 
measures, yielding ~200 charts with corresponding tables (an example is shown in Figure 1). 
Data are searchable and graphics customizable. The teams continue to review new topics 
and measures for inclusion, based on published evidence.
CHALLENGES
Integrating information from the wide array of disparate data sources available represents a 
key challenge. Meeting regulatory requirements for timely data procurement, data privacy, 
consensus on appropriate topics, measures, and denominators for population-based 
surveillance, handling of missing data, and maintaining an effective dissemination strategy 
are some of the other important challenges.
CONCLUSIONS
The US CKD Surveillance System was created to provide timely and detailed information 
on important aspects of CKD to ensure a systematic, comprehensive, and user-friendly 
product relevant to medical professionals, researchers, and policy makers alike. It has the 
potential to inform policy makers and have an impact on policy as well as provide impetus 
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for implementation of robust population-based strategies to stem the burden of CKD, reduce 
complications and cost, and improve the lives of patients with CKD.
CKD IN EUROPE
The European Renal Association—European Dialysis and Transplant Association
The European Renal Association—European Dialysis and Transplant Association registry 
has an extensive amount of data on the incidence and prevalence of RRT from the majority 
of the European countries. However, data on the prevalence of CKD in Europe are still 
scarce. In 2008, Zhang and Rothenbacher10 reported about eight European studies 
investigating the prevalence of CKD in the general population in seven different countries. 
In 2012, McCullough11 found 13 studies that investigated CKD prevalence in diverse 
populations from seven European countries. Both reviews noted different definitions of 
CKD and this wide variation in definitions for prevalence of CKD complicates attempts to 
compare the burden of CKD between countries.
The aim of the European CKD Burden Consortium is (1) to compare the prevalence and 
progression of CKD in subjects not on RRT across Europe, and apply uniform definitions 
and (2) to explain potential international differences in CKD prevalence and progression by 
healthcare system characteristics.
First, a literature review was performed to identify all European studies that could provide 
data on CKD prevalence. Studies on CKD prevalence were performed in diverse 
populations, such as adult general populations and elderly general populations.
The representatives of all eligible studies received a questionnaire on the availability of data 
and health-care system characteristics. We received completed questionnaires from 44 
studies with data on CKD prevalence from 21 different countries. On the basis of the new 
Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline12 and the 
availability of data in participating studies, standardized definitions for CKD prevalence 
were established (see Table 1). Although the use of the chronicity criterion is recommended 
by the Kidney Disease: Improving Global Outcomes, we did not include it in the definition 
as it was only available in four studies.
These standardized definitions and the CKD-EPI equation are being used to extract the 
prevalence of CKD by means of a syntax for various subgroups such as age group, gender, 
diabetic status, and body mass index status. In some countries, CKD prevalence data 
collection is limited to a specific age group (e.g., ages 65 years and older), and therefore we 
will provide only an age-specific prevalence number for these countries.
All CKD prevalence data will be age- and sex-standardized to the EU27 population. Data 
from about 19 general population-based studies originating from 13 countries across Europe 
will be included. The national differences in comorbidities and health-care system 
characteristics will be used to explain the potential differences in CKD prevalence. Later in 
2013, the data collection on the progression of CKD will start.
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Finally, identifying the prevalence and progression of CKD together with the international 
differences in health-care system characteristics should lead to a complete overview of the 
burden of CKD in Europe.
Funding—The research leading to these results has received funding from QUEST and the 
European Community’s Seventh Framework Programme under grant agreement number 
HEALTH-F2-2009-241544 (SysKID).
CKD SURVEILLANCE IN AUSTRALIA
CKD Queensland Registry
CKD is a major public health problem in Australia.13 The ANZDATA registry constitutes 
an excellent, long-term repository of information on patients on RRT in Australia,14 but the 
only CKD monitoring systems are through eKiDNAA coalition of several renal specialist 
users of Audit 4 software15 and now, on a regional basis, through the registry of CKD 
Queensland (CKD.QLD).16
The CKD.QLD registry, established in 2009, is a research and practice improvement 
platform in which all public renal specialty practices in the state of Queensland participate 
under the jurisdiction of Queensland Health. Queensland is the second largest state in 
Australia with a geographical area of 1,852,642 km2 and a population of 4.6 million, whose 
composition is representative of the aggregate Australian population of 23 million.17 This 
collaborative of public renal services embraces 80 senior practitioners (doctors and nurses) 
across 12 major hospital-based regional hubs, many with multiple clinics. There are various 
CKD service delivery models, which include hospital-associated practices, community 
clinics, and nurse practitioner–led clinics, with and without allied multidisciplinary teams.
The CKD.QLD registry will ultimately include all prevalent CKD patients from these clinics 
and recruit new patients as they are referred. Information that has been captured for clinical 
purposes in these renal practices in various formats, which include Excel, Audit 4, and web-
based programs, is consolidated by the CKD.QLD registry into a repository and manipulated 
into standard definitions.
Recruitment of patients, with informed consent, began in June 2011, with 5,000 of an 
estimated 10,900 patients enrolled so far. By May 2014, 2,500 people will have been 
followed for 2 or more years, and 4,500 will have been followed for at least 1 year. Cross-
sectional profiles of patients have been described in five of the service hubs, with 
longitudinal outcomes for at least a year described in all. In one metropolitan site, 47% of 
CKD patients with a follow-up for at least 12 months had been hospitalized on one or more 
occasions for reasons other than, or independent of, RRT.
There are some differences between the CKD.QLD registry patients and those starting RRT 
in Australia. Notably, the CKD population includes older people with no gender difference, 
unlike the male-dominated RRT population, and has a greater proportion of patients with 
renal vascular disease but a lower proportion with diabetic nephropathy.
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The CKD.QLD registry also provides a platform for interactive research, with data from the 
registry as the critical hub. Current and planned projects include epidemiologic studies, 
practice improvement projects, biomarker research, clinical trials, and health economic 
evaluations. We are also establishing a CKD Bio-bank, the first in Australia. Four PhD 
students are engaged in projects on epidemiology, renal supportive and palliative care, and 
genomics.
Significant challenges to the registry include the time required to gain informed consent and 
the different degree of detail of captured data among sites. Data capture will be simplified 
with unrolling of the Queensland Health’s electronic health record system. The biggest 
challenge, however, is that of ongoing funding to support registry activities. Currently, the 
CKD.QLD registry is funded by Queensland Health (in-kind), Amgen, Roche, Australia’s 
National Health and Medical Research Council, and the Colonial Foundation of Australia. 
We expect the translational outcomes generated through the registry to attract long-term 
funding from Queensland Health, the chief potential benefactor.
The CKD.QLD registry, endorsed by Kidney Health Australia and supported by Amgen, is 
also promoting development of a national collaborative CKD surveillance network.
Funding—The CKD.QLD registry is supported by Amgen, Roche, NHMRC Australia 
(Australian Fellowship—Wendy Hoy), the Colonial Foundation of Australia (an untied grant 
to Wendy Hoy), and Queensland Health in-kind.
CKD SURVEILLANCE IN ENGLAND
CKD domain of the UK Primary Care Quality and Outcomes Framework (QoF)
In 2005, a national strategy for early detection and prevention of CKD was published as part 
of a comprehensive policy to improve outcomes and experience of care across the whole 
kidney care pathway.18 All UK laboratories adopted automatic estimated glomerular 
filtration rate (eGFR) reporting using the four-variable MDRD equation, supported by a 
national isotope dilution mass spectrometry traceable creatinine measurement quality control 
program. Creatinine and eGFR results were transferred electronically to primary care 
electronic patient record systems. In 2006, a CKD domain was introduced into the UK 
Primary Care QOF, a pay-for-performance system, that required all primary care practices to 
establish a register for adults with CKD stages 3–5, measure and achieve blood pressure 
targets, and prescribe renin–angiotensin system blockers.19
The National Institute for Health and Clinical Excellence produced a national clinical 
guideline for the early identification and management of CKD in adults in primary and 
secondary care in 2008.20 Despite concerns about the accuracy of MDRD eGFR as a 
measure of kidney function and challenges to the concept of CKD, especially in older 
people, the approach had broad support from health-care professional and patient 
organizations. Postgraduate and continuing professional development education helped 
address the knowledge gap, and the primary care training curriculum was revised to include 
kidney disease. Initially, there was an increase in referrals to secondary care but this has now 
stabilized.
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Impact—In 2006, 1.9 million people previously unrecognized as having CKD were 
registered in primary care, many from pre-existing chronic disease programs including 
diabetes and hypertension.19 This represented 3.2% of the adult population but variance 
between practices in CKD registrations on the QOF system was high reflecting largely a 
lack of confidence in discussing kidney disease with patients and uncertainty regarding the 
importance of CKD. People with CKD are now also identified by the NHS Health Check 
program that started in 2008 and offers vascular risk assessment to all those between 40 and 
75 years of age, as well as by routine care. Currently two-thirds of those expected to have 
CKD stages 3–5, based on the nationally representative Health Survey for England 
prevalence projections, are registered with the QOF system. Practice variation ascertainment 
has now fallen, although it is still present.19,21
In one primary care study of over 10,000 confirmed CKD stage 3–5 patients, the proportion 
achieving blood pressure target (145/80) increased from 42% before the induction of QoF 
CKD registers to 50% in the 2 years post QoF and this was maintained in the most recent 
period.22 In 2010/11, CKD patients achieving blood pressure (BP) <140/85 in the last 15 
months varied by Primary Care Trust from 69 to 81%, and from 86 to 95% for patients with 
hypertension and proteinuria, respectively, who were prescribed a RAS inhibitor.19,23 
Quantification of albuminuria was added to QoF in 2009, raising awareness of proteinuria as 
an independent vascular risk factor. Guidance on renin–angiotensin system blockade is now 
restricted to those with proteinuria.
Fewer patients were referred late for consideration of RRT and unplanned initiation of 
dialysis has fallen in the United Kingdom from 28% in 2005 to 21% in 2010.24 An 
increasing number of people start RRT with a pre-emptive transplant and over the past 4 
years the incidence of RRT has levelled off at 109 PMP.24 This is despite the increasing age 
of the population and more obesity and diabetes, and it may represent a range of factors 
including better management of CKD progression and increasing provision of conservative 
kidney care as an alternative choice to RRT in those with frailty and multi-morbidity.
CKD identification and management were introduced into the national Cardiovascular 
Disease Outcomes Strategy published in 2013. Introduction of a professionally led national 
primary care CKD audit and quality improvement program and acute kidney injury 
initiatives to improve safety and medicine management in CKD are all being planned or 
implemented.
CKD SURVEILLANCE IN JAPAN
CKD-Japan cohort
CKD is prevalent (12.9%) in Japan. Until now, most epidemiological studies in Japan have 
been performed in mild CKD. CKD-Japan cohort was launched to investigate the 
comorbidities, treatment, and clinical outcomes, and to detect risk factors for CKD 
progression, death, cardiovascular disease, QOL, hospitalization, and medical cost in 
Japanese patients with CKD stage 3–5 (eGFR 10–59).25 Study design is summarized in 
Table 1. Although 91.9% were hypertensive, BP was relatively well controlled and ACEI or 
ARB was used in most patients. Compared with the Western countries, although a history of 
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ischemic heart disease was much lower (<15%), stroke history was more common (11.5%). 
Diabetic patients had higher incidence of comorbidities.26 The prevalence of anemia 
(hemoglobin<11.5 g/dl) is high, although the number of patients treated with erythropoiesis 
stimulating agents is low.27 From a data of 1,075 patients who underwent ambulatory blood 
pressure monitoring, factors affecting BP differences between office and home and the 
patterns of nocturnal BP change were analyzed. Masked hypertension was high (31%) 
among CKD patients, suggesting that home BP is critical for appropriate BP control. Low 
GFR, diabetes, and winter season were associated with higher BP and abnormal BP 
patterns.28 Inverse relationship between left ventricular hypertrophy and eGFR was 
demonstrated.29 All data are now being fixed and further analyzed to elucidate the predictive 
factors for CKD progression, ESKD development, and cardiovascular disease, as well as 
factors associated with QOL and medical costs. The CKD-Japan cohort has been 
implemented smoothly according to its time line because of a strong connection with 
Japanese Society of Nephrology and funding support from industry. Collaboration with 
CRIC also raised the motivation of our study members. Towards the future of the CKD-
Japan cohort, we must address the issues including fund-raising, follow-up of patients for 
longer periods, and participation in the international network for CKD cohort.
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Figure 1. Percentage who were aware of their kidney disease by level of albuminuria and 
estimated glomerular filtration rate (eGFR), National Health and Nutrition Examination Survey, 
1999–2010 Centers for Disease Control and Prevention
Chronic Kidney Disease Surveillance System—United States. The US Department of Health 
and Human Services. http://www.cdc.gov/ckd/surveillance.
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Table 1






 <60 ml/min/1.73 m2
2 eGFR
a
 <60 ml/min/1.73 m2
1 and 2 No chronicity criterion
b
Abbreviation: eGFR, estimated glomerular filtration rate.
a
eGFR calculated using the CKD-EPI formula.
b
Chronicity criterion (persistence of albuminuria or decreased eGFR for ≥3 months) could not be used as only four studies had this available.
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